Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

HIV-1 drug resistance: where do polymorphisms fit in?

Theys K, Abecasis AB, Vandamme AM.

Future Microbiol. 2013 Mar;8(3):303-6. doi: 10.2217/fmb.13.10. No abstract available.

PMID:
23464368
2.

Indinavir resistance evolution: a comment.

Wiwanitkit V.

Virol Sin. 2011 Feb;26(1):72. doi: 10.1007/s12250-011-3173-6. Epub 2011 Feb 18. No abstract available.

PMID:
21331894
3.

Drug-resistant HIV infection among drug-naive patients in Israel.

Grossman Z, Lorber M, Maayan S, Bar-Yacov N, Levy I, Averbuch D, Istomin V, Chowers M, Sthoeger Z, Ram D, Rudich H, Mileguir F, Pavel R, Almaliach R, Schlaeffer F, Kra-Oz Z, Mendelson E, Schapiro JM, Riesenberg K.

Clin Infect Dis. 2005 Jan 15;40(2):294-302. Epub 2004 Dec 20.

PMID:
15655750
4.

Indinavir resistance evolution in one human immunodeficiency virus type 1 infected patient revealed by single-genome amplification.

Geng QM, Li HP, Bao ZY, Liu YJ, Zhuang DM, Li L, Liu SY, Li JY.

Virol Sin. 2010 Oct;25(5):316-28. doi: 10.1007/s12250-010-3122-4. Epub 2010 Oct 8.

PMID:
20960178
5.

Prevalence of drug resistance-related mutations among HIV-1s in Japan.

Sugiura W, Matsuda M, Abumi H, Yamada K, Taki M, Ishikawa M, Miura T, Fukutake K, Gouchi K, Ajisawa A, Iwamoto A, Hanabusa H, Mimaya J, Takamatsu J, Takada N, Kakishita E, Yoshioka A, Kashiwagi S, Shirahata A, Nagai Y.

Jpn J Infect Dis. 1999 Feb;52(1):21-2. No abstract available.

PMID:
10808258
6.

Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras.

Murillo W, Paz-Bailey G, Morales S, Monterroso E, Paredes M, Dobbs T, Parekh BS, Albert J, Rivera IL.

J Clin Virol. 2010 Dec;49(4):239-44. doi: 10.1016/j.jcv.2010.03.013. Epub 2010 Apr 22.

PMID:
20417152
7.

HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia.

Hamers RL, Siwale M, Wallis CL, Labib M, van Hasselt R, Stevens WS, Schuurman R, Wensing AM, Van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance.

J Acquir Immune Defic Syndr. 2010 Sep;55(1):95-101. doi: 10.1097/QAI.0b013e3181e544e0.

PMID:
20585262
8.

Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.

Zolopa AR.

J Infect Dis. 2006 Sep 15;194 Suppl 1:S59-64. Review.

PMID:
16921474
9.

High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.

Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D.

Antivir Ther. 2011;16(3):429-33. doi: 10.3851/IMP1754.

PMID:
21555827
10.

Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy.

Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A; EuroSIDA group.

J Antimicrob Chemother. 2011 Apr;66(4):901-11. doi: 10.1093/jac/dkr006. Epub 2011 Jan 31.

PMID:
21393179
11.

Update of the drug resistance mutations in HIV-1: December 2009.

Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.

Top HIV Med. 2009 Dec;17(5):138-45. Review. No abstract available.

12.

HIV drug resistance tests: an update on methods for calculating phenotypic fold change from a viral genotype.

Bellosillo NA, Bacheler L, Villacian J.

Clin Infect Dis. 2009 Mar 1;48(5):687; author reply 687. doi: 10.1086/597016. No abstract available.

PMID:
19191661
13.

HIV-1 integrase variability and relationship with drug resistance in antiretroviral-naive and -experienced patients with different HIV-1 subtypes.

Reigadas S, Marcelin AG, Houssaïni A, Yerly S, Descamps D, Plantier JC, Ruffault A, Amiel C, Trabaud MA, Flandre P, Fleury H, Masquelier B; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2013 Apr;68(4):969-72. doi: 10.1093/jac/dks474. Epub 2012 Nov 25. No abstract available.

PMID:
23184711
14.

Antiretroviral resistance.

Geretti AM.

J HIV Ther. 2006 Dec;11(4):72-3. No abstract available.

PMID:
17578209
15.

Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.

Mantovani NP, Azevedo RG, Rabelato JT, Sanabani S, Diaz RS, Komninakis SV.

J Clin Microbiol. 2012 Jun;50(6):2122-5. doi: 10.1128/JCM.00539-12. Epub 2012 Mar 7.

16.

2011 update of the drug resistance mutations in HIV-1.

Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer R, Wensing AM, Richman DD.

Top Antivir Med. 2011 Nov;19(4):156-64. Review.

17.

Assessments of HIV drug resistance mutations in resource-limited settings.

Jordan MR.

Clin Infect Dis. 2011 Apr 15;52(8):1058-60. doi: 10.1093/cid/cir093. No abstract available.

PMID:
21460325
18.

Transmission of zidovudine resistant strains of HIV-1: the first wave.

Blower S.

AIDS. 2001 Nov 23;15(17):2317-8. No abstract available.

PMID:
11698706
19.

Evolutionary pathways of transmitted drug-resistant HIV-1.

Pingen M, Nijhuis M, de Bruijn JA, Boucher CA, Wensing AM.

J Antimicrob Chemother. 2011 Jul;66(7):1467-80. doi: 10.1093/jac/dkr157. Epub 2011 Apr 18. Review.

PMID:
21502281
20.

[Prevalence of antiretroviral drug genotypic resistance among HIV patients in Cuenca, Spain].

Rodriguez-Escudero MJ, Prada de Medio E, Rosa Herranz C, Martinez Medina MC, Franquelo Gutierrez R.

Rev Esp Quimioter. 2007 Jun;20(2):203-5. Spanish.

Supplemental Content

Support Center